Table 3.
Major Infection Classification and Dosing of Oritavancin, Single- and Multiple-Dose Oritavancin Regimensa
| Infection Classification and Dosing | no./No. (%) |
|---|---|
| Skin and soft tissue | 401/440 (91.1) |
| Single dose | 380/401 (94.8) |
| Multiple dose | 21/401 (5.2) |
| Bacteremia | 7/440 (1.6) |
| Single | 7/7 (100) |
| Multiple | 0/7 (0) |
| Other | 32/440 (7.3) |
| Osteomyelitis | 18/32 (56.3) |
| Single dose | 10/18 (55.6) |
| Multiple dose | 8/18 (44.4) |
| Septic arthritis, synovitis | 4/32 (12.5) |
| Single dose | 2/4 (50.0) |
| Multiple dose | 2/4 (50.0) |
| Prosthetic joint infection | 3/32 (9.4) |
| Single dose | 2/3 (66.7) |
| Multiple dose | 1/3 (33.3) |
| Otherb | 7/32 (21.9) |
| Single dose | 7/7 (100) |
| Multiple dose | 0/7 (0) |
aMultiple-dose oritavancin includes treatment courses in which doses were interrupted by no more than 14 days. For skin and soft tissue, multiple doses include cellulitis (n = 10), wound (n = 8), abscess (n = 2), and burn (n = 1).
bIncludes catheter exit site, 1; infected bursa, 3; maxillary sinus infection, 1; hardware, posterior lumbar tissue, 1; and lymphadenitis, 1.